arrow_back Back to App

NMOSD Research Support: New Consortium and Funding

This act establishes a national consortium to combat the rare neurological disease NMOSD, which leads to blindness and paralysis. Its aim is to accelerate research into the causes, treatment, and biomarkers of the disease, potentially improving the quality of life for patients and their families. $25 million annually is allocated for this purpose until 2024.
Key points
A National Neuromyelitis Optica Spectrum Disorder Consortium will be established to coordinate research on this rare disease.
The Consortium will provide grants for research, collect data, and develop treatment standards, aiming to find more effective therapies.
The act allocates $25 million annually for fiscal years 2021-2024 to fund these efforts, increasing the chances of progress in combating the disease.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_254
Sponsor: Rep. Lee, Barbara [D-CA-13]
Process start date: 2021-01-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Neuromyelitis Optica Spectrum Disorder Consortium Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_254.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-01-11.

What are the main provisions?

Key points include:

  • A National Neuromyelitis Optica Spectrum Disorder Consortium will be established to coordinate research on this rare disease.
  • The Consortium will provide grants for research, collect data, and develop treatment standards, aiming to find more effective therapies.
  • The act allocates $25 million annually for fiscal years 2021-2024 to fund these efforts, increasing the chances of progress in combating the disease.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Lee, Barbara [D-CA-13].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health